Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban plus clopidogrel for prevention of recurrent ischemic stroke in atrial fibrillation with cerebral atherosclerosis
KCT0011194Phase 4Not yet recruiting
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of apixaban and clopidogrel in Atrial fibrillation (AFib), cerebral arteriosclerosis and ischemic stroke, sponsored by Samjin Pharmaceutical Co., Ltd. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
apixabanclopidogrel
03
Conditions
Atrial fibrillation (AFib)cerebral arteriosclerosisischemic stroke
Beyond the preview
Go deeper on KCT0011194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011194.